Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of experts
Roger von Moos(Kantonsspital Graubünden), Axel Hauschild(University Hospital Schleswig-Holstein), Matti Aapro(Clinique de Genolier), Domenica Lorusso(Agostino Gemelli University Polyclinic), Jürgen Lademann(Charité - Universitätsmedizin Berlin), Karen Harrold(Mount Vernon Cancer Centre), Florian Scotté(Université Paris-Saclay), Daniel Rayson, Reinhard Dummer(University Hospital of Zurich), Jalid Sehouli(Charité - Universitätsmedizin Berlin), Beat Thuerlimann(Kantonsspital St. Gallen), Mario E. Lacouture(Garden City Community College)
Cited by 128
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k